Drugs / STI-1386
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05361954 | Aug 2023 → Oct 2026 expected | malignant pancreatic neoplasm, sarcoma | Sorrento Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STI-1386 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05361954 ↗ |
| Modality | Other / unclassified | “STI-1386, an oncolytic virus” NCT05361954 ↗ |